MeiraGTx (NASDAQ:MGTX) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded MeiraGTx (NASDAQ:MGTX) from a "sell" to a "hold" rating, contributing to a "Moderate Buy" consensus among analysts with an average price target of $23.67. The company recently reported a surprise quarterly EPS of $0.19 against an estimated -$0.60 and revenue of $75.36 million, significantly exceeding expectations, despite remaining unprofitable with a -140.31% net margin. Additionally, CEO Alexandria Forbes sold 62,000 shares, and institutional investors collectively hold about 67.5% of the company's stock.
(MGTX) Movement Within Algorithmic Entry Frameworks
Meiragtx Holdings Plc (NASDAQ: MGTX) exhibits strong sentiment across all time horizons, supporting an overweight bias according to Stock Traders Daily's AI analysis. The report identifies a mid-channel oscillation pattern and highlights an exceptional 46.0:1 risk-reward short setup. Three distinct trading strategies are provided, catering to various risk profiles and holding periods, along with multi-timeframe signal analysis for support and resistance levels.
MGTX Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for MeiraGTx Holdings PLC (MGTX). As of April 2, 2026, the overall technical sentiment for MGTX is a "Strong Buy," based on a combination of moving averages and oscillators, despite some indicators showing "Sell" signals. Key metrics like MACD and various moving averages suggest bullish momentum, while RSI, Stochastic Oscillator, and CCI suggest the stock is in overbought territory.
MeiraGTx Holdings plc Ordinary Shares (MGTX) Stock Price Today & Analysis
This article provides a detailed analysis of MeiraGTx Holdings plc Ordinary Shares (MGTX) stock, including its current price performance, fundamental financials, and company overview. It also offers a guide on how to buy MGTX stock via the Gotrade app, addresses common investment questions, and mentions recent related news.
MeiraGTx Holdings PLC $MGTX Shares Bought by Hennion & Walsh Asset Management Inc.
Hennion & Walsh Asset Management Inc. significantly increased its stake in MeiraGTx Holdings PLC (MGTX) by 183.1% in Q4, bringing its total to 308,509 shares valued at approximately $2.45 million, contributing to institutional investors owning 67.48% of the company. Despite a surprise earnings beat with EPS of $0.19 against an expected -$0.60 and robust revenue of $75.36 million, the company still faces negative margins and an anticipated fiscal year EPS of -1.48. Analyst sentiment remains mixed, earning a "Moderate Buy" consensus with a price target of $23.67, even as CEO Alexandria Forbes recently reduced her personal holdings.
Strength Displayed by MeiraGTx (MGTX): Will Its 6.2% Surge Lead to Further Gains?
MeiraGTx (MGTX) shares surged 6.2% following strong Q4 and full-year 2025 financial results and FDA Breakthrough Therapy designation for its dry mouth therapy. Despite this, future gains are uncertain as analysts anticipate a quarterly loss and have recently revised earnings estimates downwards. The company currently holds a Zacks Rank #3 (Hold), contrasting with CorMedix (CRMD)'s Zacks Rank #4 (Sell) in the same sector.
Strength Displayed by MeiraGTx (MGTX): Will Its 6.2% Surge Lead to Further Gains?
MeiraGTx Holdings PLC (MGTX) saw a 6.2% stock surge after reporting strong Q4 and full-year 2025 financial results and receiving Breakthrough Therapy designation from the FDA for its AAV2-hAQP1 therapy. While analysts predict a quarterly loss, revenue is expected to increase significantly. Investors are advised to monitor MGTX, especially since earnings estimates have been adjusted downward, which typically does not support further price gains, despite the recent positive momentum.
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
MeiraGTx (MGTX) shares experienced a 6.2% surge driven by robust trading volume and strong Q4/full-year 2025 financial results, alongside the FDA granting Breakthrough Therapy designation for its AAV2-hAQP1 treatment. However, despite this jump, the stock carries a Zacks Rank #3 (Hold) due to a 5.6% lower revision in the consensus EPS estimate over the last 30 days, suggesting a need for caution. Investors should monitor MGTX closely for sustained strength.
MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
MeiraGTx Holdings plc recently released its annual results, showing impressive revenue exceeding forecasts by 676% and narrower-than-expected losses. However, analysts have since cut their revenue outlooks for 2026 and expect increased losses per share, despite maintaining an unchanged average price target. The company is still projected to grow revenue faster than the wider industry at 37% annually.
MeiraGTx 2025 10-K: Revenue $81.4M, EPS (1.42)
MeiraGTx reported 2025 fiscal revenue of $81.4 million, a significant increase from $33.3 million in 2024, primarily due to a $75.0 million license payment from Lilly. The company's net loss improved to $(114.2) million from $(147.8) million, and diluted net loss per share narrowed to $(1.42) from $(2.12). Key business highlights include strategic partnerships, regulatory milestones for its AAV programs, expansion of manufacturing capabilities, and advancements in its riboswitch platform.
MeiraGTx (NASDAQ: MGTX) expands gene therapy partnerships and manufacturing
MeiraGTx details a robust gene therapy pipeline and strategic partnerships in its annual report, highlighting advancements in xerostomia, Parkinson's disease, and inherited retinal disorders. The company's in-house manufacturing capabilities and transformative riboswitch gene regulation platform are central to its strategy and supported by significant collaborations with Johnson & Johnson, Hologen, and Eli Lilly, which provide substantial non-dilutive capital and milestone potential. MeiraGTx has received FDA Breakthrough Therapy and RMAT designations for its lead programs, indicating strong potential for accelerated development and approval.
MeiraGTx Holdings PLC (MGTX) Q4 Results Exceed Expectations for Earnings and Revenue
MeiraGTx Holdings PLC (MGTX) reported strong Q4 results, significantly exceeding earnings and revenue expectations. The company posted earnings of $0.19 per share against an anticipated loss of $0.60, and revenue reached $75.36 million, far surpassing forecasts. Despite a year-to-date decline in share price, the positive performance and mixed analyst revisions suggest a "Hold" rating for the stock in the near term.
MeiraGTx Holdings PLC (MGTX) Q4 earnings and revenues surpass estimates
MeiraGTx Holdings PLC (MGTX) reported its Q4 earnings and revenues, exceeding analyst estimates. This positive financial performance indicates a strong close to the year for the company. The specific details of the earnings and revenue figures would provide more insight into the company's operational success.
MeiraGTx Holdings PLC (MGTX) Q4 earnings and revenues surpass estimates
This article states that MeiraGTx Holdings PLC (MGTX) reported fourth-quarter earnings and revenues that exceeded analyst estimates. No further financial details or commentary were provided.
Piper Sandler Lowers MeiraGTx (NASDAQ:MGTX) Price Target to $26.00
Piper Sandler has reduced its price target for MeiraGTx (NASDAQ:MGTX) to $26.00 from $30.00, while maintaining an "overweight" rating. This adjustment comes despite the company reporting strong quarterly earnings and receiving FDA Breakthrough Therapy Designation for its AAV2-hAQP1 program. The article notes mixed analyst views, with an average target of $23.67, and highlights a recent insider sale by CEO Alexandria Forbes.
Piper Sandler cuts MeiraGTx stock price target on valuation
Piper Sandler has cut its price target for MeiraGTx Holdings plc (NASDAQ:MGTX) to $26.00 from $30.00, while maintaining an Overweight rating. This adjustment follows a fiscal year 2025 update from the biotechnology company, which included an FDA Breakthrough Therapy Designation for its AAV2-hAQP1 therapy and a planned clinical trial for AAV-GAD in Parkinson’s disease. Other analysts have also adjusted targets, and MeiraGTx has recently secured licensing agreements and initiated a share repurchase program.
MeiraGTx (NASDAQ:MGTX) Price Target Raised to $16.00 at Bank of America
Bank of America has increased its price target for MeiraGTx (NASDAQ:MGTX) to $16.00, maintaining a "Buy" rating, following the company's unexpected quarterly earnings beat and the FDA granting Breakthrough Therapy designation for one of its therapies. Despite these positive developments, MGTX faces challenges with profitability, negative net margins, and recent insider stock sales by its CEO, which could influence investor sentiment. MeiraGTx, a clinical-stage biotechnology company, is focused on developing gene therapies for rare diseases using AAV vectors.
BofA raises MeiraGTx stock price target to $16 on FDA designation
BofA Securities has increased its price target on MeiraGTx Holdings plc (NASDAQ:MGTX) to $16.00 from $14.00, reiterating a Buy rating. This adjustment comes after the FDA granted Breakthrough Therapy Designation for the company's AAV2-hAQP1 program, significantly derisking one of MeiraGTx's late-stage assets. The firm foresees xerostomia as a major source of value creation for the company in the coming years.
BofA raises MeiraGTx stock price target to $16 on FDA designation
BofA Securities has raised its price target for MeiraGTx Holdings plc (NASDAQ:MGTX) to $16.00 from $14.00, maintaining a Buy rating. This adjustment follows the FDA's Breakthrough Therapy Designation for the company's AAV2-hAQP1 program, addressing radiation-induced xerostomia. The firm highlighted this designation as a significant de-risking factor for a late-stage asset and increased its market penetration assumption for the xerostomia treatment.
MGTX SEC Filings - Meiragtx Holdings Plc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Meiragtx Holdings Plc (MGTX) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details the company's use of these reports to communicate financial results, strategic collaborations, and regulatory milestones, particularly highlighting its partnerships with Eli Lilly and Hologen Limited. The platform also offers real-time updates from EDGAR and AI-powered summaries to help users understand key points from these regulatory disclosures.
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) reported strong Q4 results, with earnings of $0.19 per share significantly beating analyst expectations of a loss of $0.6 per share. The company also surpassed revenue estimates, posting $75.36 million against a consensus estimate with a substantial margin. Despite these strong results, the stock has underperformed the S&P 500 year-to-date, and investors are now looking towards management's commentary and future earnings outlook.
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
MeiraGTx received FDA Breakthrough Therapy Designation for its AAV2-hAQP1 treatment for radiation-induced xerostomia and reported its fourth-quarter and full-year 2025 financial results. The company also provided updates on its Parkinson's and ophthalmology programs, including strategic collaborations with Eli Lilly and Hologen AI, and detailed its Riboswitch gene regulation technology platform. MeiraGTx ended 2025 with $65.9 million in cash and expects its current capital to fund operations into the second half of 2027.
MeiraGTx Extends Perceptive Notes to May 2027, Plans $25M Redemption; Warrants Repriced to $8
MeiraGTx (MGTX) has amended its agreement with Perceptive to extend the maturity of its notes from August 2026 to May 2027 and plans to redeem $25 million of principal by June 2026. Additionally, the exercise price of related warrants has been reduced to $8.00 per share. These changes aim to improve the company's liquidity and financial flexibility while reducing its debt.
MeiraGTx (Nasdaq: MGTX) gains FDA breakthrough tag and extends debt maturity
MeiraGTx (Nasdaq: MGTX) has extended its debt maturity with Perceptive from August 2, 2026, to May 2, 2027, committing to redeem $25 million by June 30, 2026. The company also secured FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia and reported 2025 revenue of $81.4 million, driven by a $75 million license payment from Eli Lilly, with a net loss of $114.2 million. MeiraGTx believes its existing cash, receivables, and collaboration funding will support operations into the second half of 2027 and cover scheduled debt repayments.
MeiraGTx Holdings (MGTX) Q3 Loss Of US$50.5m Reinforces Bearish Community Narratives
MeiraGTx Holdings recently reported a Q3 FY 2025 loss of US$50.5 million on just US$0.4 million in revenue, reinforcing bearish narratives about the gene therapy company. Despite a forecast of 51.2% annual revenue growth, MeiraGTx has a history of increasing losses, negative shareholders' equity, and trades at a high P/S ratio of 22.1x compared to biotech peers. The company is not projected to be profitable within the next three years, leading to investor caution regarding its long-term financial stability.
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) reported strong Q4 results, with earnings of $0.19 per share significantly beating the Zacks Consensus Estimate of a $0.6 loss, representing a +131.67% surprise. The company's revenues also surpassed expectations, reaching $75.36 million against an estimate of $2.41 million. Despite these positive results, MGTX shares have seen a 4.2% decline year-to-date, slightly more than the S&P 500's 3.7% decrease.
Meiragtx Holdings Insider Sold Shares Worth $459,420, According to a Recent SEC Filing
An insider at MeiraGTx Holdings has reportedly sold shares valued at $459,420, according to a recent SEC filing. The company, a clinical-stage gene therapy firm, focuses on ocular, xerostomia, and neurodegenerative diseases. This transaction comes amidst various other company news including licensing agreements, price target adjustments, and share repurchases.
MeiraGTx (NASDAQ:MGTX) CEO Sells $459,420.00 in Stock
MeiraGTx CEO Alexandria Forbes sold 62,000 shares of the company's stock for $459,420 on March 24, reducing her stake by 4.1%. Following the transaction, Forbes now owns 1,449,695 shares valued at approximately $10.74 million. The company's stock opened at $7.41, with a market capitalization of $596.43 million, and analysts currently rate it as a "Moderate Buy" with a consensus price target of $26.00.
Insider Sell Alert: Alexandria Forbes Sells 62,000 Shares of MeiraGTx Holdings PLC
Alexandria Forbes, President & CEO of MeiraGTx Holdings PLC (MGTX), sold 62,000 shares of the company on March 24, 2026. This transaction adds to her total of 204,500 shares sold over the past year, with no insider purchases. The stock is currently trading at $7.41, deemed fairly valued against its GF Value of $7.17.
Forbes Alexandria, president & CEO of MeiraGTx, sells $459k in MGTX stock
Alexandria Forbes, President and CEO of MeiraGTx Holdings plc, sold 62,000 shares of MGTX stock for approximately $459,420 on March 24, 2026, under a Rule 10b5-1 trading plan. After the sale, Forbes directly owns 1,449,695 ordinary shares. This transaction follows recent strategic moves by MeiraGTx, including a licensing agreement with ZipBio and a share repurchase from Perceptive Life Sciences Master Fund.
[144] MeiraGTx Holdings plc SEC F... | MGTX SEC Filing - Form 144
MeiraGTx Holdings plc has filed a Form 144 with the SEC, indicating a proposed sale of 62,000 Ordinary Shares. The shares, with an aggregate market value of $459,420, were acquired through an incentive compensation stock grant on June 7, 2018. The proposed sale is scheduled for March 24, 2026, and will be handled by Merrill Lynch on NASDAQ.
MeiraGTx (MGTX) CEO sells 62K shares at $7.41 under 10b5-1 plan
MeiraGTx Holdings plc's President and CEO, Alexandria Forbes, sold 62,000 Ordinary Shares of MGTX at a weighted average price of $7.41 per share, consistent with a pre-arranged Rule 10b5-1 trading plan established in November 2025. Following this transaction, Forbes retains 1,449,695 Ordinary Shares. The sale occurred in multiple transactions with prices ranging from $7.27 to $7.56.
Forbes Alexandria, president & CEO of MeiraGTx, sells $459k in MGTX stock
Alexandria Forbes, President and CEO of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 62,000 shares of the company’s stock for approximately $459,420 on March 24, 2026. This insider sale occurs as MeiraGTx faces financial headwinds, including a low current ratio and significant cash burn, although InvestingPro analysis suggests the stock may be undervalued. Despite these challenges, the company has recently engaged in strategic moves such as a licensing agreement with ZipBio for gene therapy treatments and a share repurchase agreement with Perceptive Life Sciences Master Fund.
How (MGTX) Movements Inform Risk Allocation Models
This article analyzes Meiragtx Holdings Plc (NASDAQ: MGTX) using AI models, identifying a weak near-term sentiment but strong long-term outlook. It presents three distinct trading strategies—position, momentum breakout, and risk hedging—tailored to different risk profiles. The analysis highlights a significant 60.0:1 risk-reward setup, targeting a 16.7% gain against a 0.3% risk.
MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
MeiraGTx Holdings PLC (NASDAQ:MGTX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $26.00. Institutional investors own a significant portion of the shares, and recent financial data indicate the company has a market cap of $594.82 million with profitability and liquidity challenges. The biotechnology company focuses on developing gene therapies for rare diseases using adeno-associated virus (AAV) vectors.
MGTX PE Ratio & Valuation, Is MGTX Overvalued
MeiraGTx Holdings PLC (MGTX) is currently considered undervalued based on its forward P/S ratio and relative valuation methods, with a fair price estimated between $728.23 and $753.45 compared to its current price of $7.69. Despite being highly undervalued, its P/S ratio of 11.84 is significantly above the industry average, which, combined with negative revenue growth, suggests this premium may be unsustainable. The article also details MGTX's Price-to-Book ratio, Free Cash Flow yield, and other forward-looking valuation metrics.
MeiraGTx Holdings Stock (ISIN: US58550P1012) Faces Earnings Spotlight Amid Volatility and Analyst Optimism
MeiraGTx Holdings (NASDAQ: MGTX) is nearing its Q1 2026 earnings release, with its stock trading near $7.39. Predictive AI models suggest a strong near-term upside potential of up to 17.7%, with long-term targets reaching $50, driven by analyst optimism for its gene therapy pipeline. The company faces significant revenue decline and negative EPS in its earnings report but is buoyed by its robust gene therapy platform and potential FDA catalysts.
MeiraGTx Holdings Stock (ISIN: US58550P1012) Faces Earnings Spotlight Amid Volatility and Analyst Optimism
MeiraGTx Holdings (MGTX) stock is trading around $7.39 ahead of its earnings release, with AI models and analyst consensus signaling significant upside potential, including a target range up to $50. The company, focused on gene therapy innovations, faces high volatility but is seen as a high-growth play with a strong pipeline. European investors are particularly interested in its ophthalmology and neurodegeneration focus, aligning with regional demographics and regulatory frameworks.
Trading Systems Reacting to (MGTX) Volatility
This article from Stock Traders Daily discusses trading systems reacting to volatility in Meiragtx Holdings Plc (NASDAQ: MGTX). It presents a positive sentiment with strong near-term indicators, a neutral mid-term outlook, and a positive long-term bias. The analysis includes institutional trading strategies with specific entry, target, and stop-loss levels, alongside multi-timeframe signal analysis for support and resistance levels.
MeiraGTx (NASDAQ:MGTX) Upgraded by Zacks Research to Hold Rating
Zacks Research has upgraded MeiraGTx (NASDAQ:MGTX) from a "strong sell" to a "hold" rating. Analyst consensus for MGTX is "Moderate Buy" with an average price target of $26, despite the company's strained liquidity and high debt-to-equity ratio. Several institutional investors have also recently adjusted their holdings in the gene therapy company.
MeiraGTx Holdings PLC expected to post a loss of 57 cents a share - Earnings Preview
MeiraGTx Holdings PLC (MGTX) is projected to report a loss of 57 cents per share in its upcoming earnings release. This information is based on a Reuters earnings preview, providing an outlook for the company's financial performance.
MeiraGTx (MGTX) to Release Quarterly Earnings on Thursday
MeiraGTx (NASDAQ:MGTX) is scheduled to release its Q4 2025 earnings before the market opens on Thursday, March 12th, with analysts projecting a loss of $0.60 per share. The stock opened at $7.41, with a market capitalization of $596.43 million, and has experienced a 12-month trading range of $4.55 to $9.73. Institutional investors currently hold a significant 67.48% stake in the company, while analyst ratings are mixed, averaging to a "Moderate Buy" with a $26.00 price target.
How Meiragtx Holdings Plc (MGTX) Affects Rotational Strategy Timing
This article analyzes Meiragtx Holdings Plc (MGTX) using AI models to determine its impact on rotational strategy timing. It highlights a strong near-term sentiment moving towards a long-term positive bias, with an exceptional risk-reward setup. The analysis provides specific entry, target, and stop-loss points for position, momentum breakout, and risk hedging trading strategies across different time horizons.
Revenue per share of MeiraGTx Holdings Plc – FWB:328
This article provides financial information for MeiraGTx Holdings Plc (FWB:328), specifically focusing on its revenue per share. It is presented on TradingView, a financial platform that offers various market data and analysis tools for investors. The content is primarily a listing of financial metrics within the company's profile on the platform.
MeiraGTx Holdings Plc (MGTX): Investor Outlook With A Potential 249% Upside
MeiraGTx Holdings Plc (MGTX), a clinical-stage biotechnology company, shows significant investor interest with a potential upside of 249.22% and unanimous "Buy" ratings from analysts, targeting an average price of $26.75. Despite currently being unprofitable with a negative EPS, its strong pipeline of genetic medicine therapies and strategic collaborations position it as a compelling opportunity for investors with a high tolerance for risk. The company's valuation is driven by its research and development progress in treatments for ocular, neurodegenerative, and systemic diseases.
MeiraGTx (MGTX) CFO reports RSU vesting and tax-share withholding
MeiraGTx Holdings plc CFO & COO Richard Giroux reported the vesting of 60,000 restricted share units into ordinary shares on February 21, 2026. To cover tax obligations, 31,726 ordinary shares were withheld at $7.45 per share. Following these transactions, Giroux directly holds 1,027,530 ordinary shares, with additional indirect holdings.
MGTX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Meiragtx Holdings Plc (MGTX), including its income statement, balance sheet, cash flow, and key financial ratios through fiscal year 2024. It highlights the company's financial health, indicating weak profitability and high leverage despite strong revenue growth, with specific breakdowns of metrics like operating margin, free cash flow, and debt-to-equity ratio. The analysis also covers earnings quality, interest coverage, and an estimated cash runway, concluding with a low Piotroski F-Score and an overall weak financial profile.
MeiraGTx (MGTX) CEO vests 62,500 RSUs, withholds shares for taxes
MeiraGTx Holdings plc CEO Alexandria Forbes reported the vesting of 62,500 restricted share units on February 21, 2026, which converted into ordinary shares. To cover taxes associated with this vesting, 33,048 ordinary shares were withheld at a price of $7.45 per share. Following these transactions, Forbes directly holds 1,511,695 ordinary shares of MeiraGTx.
MeiraGTx (MGTX) CMO reports RSU vesting and tax-share withholding on Form 4
MeiraGTx Holdings plc's Chief Medical Officer, Robert K. Zeldin, reported equity award activity on February 21, 2026, involving the vesting of 7,500 restricted share units, converting them into ordinary shares. To cover tax obligations, 2,952 ordinary shares were withheld at a price of $7.45 per share, which was a tax-withholding disposition, not an open-market sale. After these transactions, Zeldin directly held 172,888 ordinary shares in the company.
市场下一个爆点：精选5只美国抗衰老股票
这篇文章探讨了抗衰老市场作为下一个投资热点，指出全球抗衰老行业规模正不断增长。文章推荐了五只在美国上市的抗衰老股票，分别是MeiraGTx Holdings, Acumen Pharmaceuticals, Lineage Cell Therapeutics, Celularity, 和Unity Biotechnology，并简要介绍了它们在研项目和市场表现。这些公司主要通过基因疗法、生物制药和干细胞技术开发治疗老年疾病和退行性疾病的药物。
